People may be at increased risk for developing diabetes for up to a year after a diagnosis of COVID-19, according to two studies. Additionally, organ donation from dying donors with current or previous COVID-19 infection is likely safe, transplant teams from the United States and Italy will report at the April 2022 European Congress of Clinical Microbiology & Infectious Diseases meeting.
AbbVie and Gedeon Richter signed an agreement to co-develop and commercialize a potential treatment for a range of neuropsychiatric diseases.
AbbVie bolstered the company’s neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Biohaven, a clinical-stage biopharmaceutical company that innovates late-stage products for neurological and neuropsychiatric diseases, announced two major growth achievements.
Less than a year after a regulatory setback, Acadia Pharmaceuticals resubmitted the company’s supplemental New Drug Application for Nuplazid (pimavanserin) as a potential treatment for hallucinations and delusions associated with dementia-related psychosis.
Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.